Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients (Neutra4)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Traxivitug (Primary)
Indications Human polyomavirus infections
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms Neutra4
Sponsors Amplyx Pharmaceuticals; Vera Therapeutics

Most Recent Events

17 Oct 2022 According to a Vera Therapeutics media release, results from this trial will be presented at the American Society of Nephrology Kidney Week 2022 Annual Meeting.
19 Jul 2022 Status changed from recruiting to completed.
08 Jun 2022 Results of an interim analysis at 12 weeks for 2 cohorts presented at the 2022 American Transplant Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com